Click on the blue marker below to find a clinical site near you.
Easing the study enrollment process
To enable easier access to the clinical trial for children and their families, 25 locations for The TAPESTRY Study are planned across the United States, Australia and New Zealand.
Eligible participants will be randomly assigned to receive AB-2004 or placebo and all study-related assessments at no cost. Expenses for travel to and from the doctor and medical visits will be paid for by Axial Therapeutics. Additional information around travel reimbursement will be provided by the trial coordinator.
More information is also available at: clinicaltrials.gov, identifier NCT04895215.
“The lack of safe and effective treatment options for co-occurring conditions associated with ASD, such as irritability and anxiety, exacerbate the daily challenges faced by children and their families.”
--Robert L. Hendren, D.O., professor, psychiatry, Weill Institute for Neurosciences at the University of California, San Francisco, School of Medicine, and a principal investigator for the AB-2004 Phase 2 trial
“I am encouraged by previous studies of AB-2004 and I look forward to assessing its potential as a safe alternative to atypical antipsychotics currently used to treat irritability associated with autism.”